

MEDICAL PRESCRIPTION FORM

GENOTYPING OF SOLID TUMORS



TWO-SIDED DOCUMENT

IMPORTANT: CHECK LIST BEFORE SHIPMENT

- ✓ What should be shipped?
 - For molecular biology testing:

2 dry tubes of chips section (5 chips section at 5µ per tube)

Please note: if < 20% tumors cells \rightarrow chips should be made after macro-dissection. If it is not possible to perform In your facility, please send us the block

For FISH analysis:

3 consecutive, unstained, 3 µ-thick sections placed on silanized slides for each probe set ordered

✓ A copy of the anatomopathological examination report corresponding to the sample must be enclosed.

PATIENT			REFERRING PRESC	CRIBING PHYSICIAN	
LAST NAME		FIRST and LAST NAME			
		Email address :			
Birth name					
Date of birth:			Mandatory	y stamp	
Gender:					
		Cignoture			
		Signature :			
INFORMATION TO BI	E COMPLETED BY	THE PATHO	LOGIST (correspon	ident)	
Sampling date:					
Anapath n°:		Mandatory stamp			
Sampling Type:					
☐ Biopsy ☐ Surgical specimen	n (recommended)				
Shipped material: Slides Sections	Signature :				
Tumor cellularity on the transmitted material (%):					
Date of shipment to the Molecular Biology laborat	tory:				
Fixative used (formalin recommended) : Formalin AFA Other:					
, ,					
Tumor material to be analyzed:					
☐ Primary tumor	☐ Colorectal		Breast	☐ Prostate	
☐ Metastasis	☐ Bronchopulmona	ary 🗆	Ovary	☐ Gallbladder	
	☐ Stomach		Endometrium	☐ Ganglion	
	Skin		Liver	☐ Bones	
	☐ Pancreas		Peritoneal	☐ Other:	



MEDICAL PRESCRIPTION FORM

GENOTYPING OF SOLID TUMORS



Laboratoire Cerba Customer relation service Tel.: +33 (0)1 34 40 97 76

Fax: +33 (0)1 34 40 21 29 Email: intgb@lab-cerba.com

Two-Sided Document

COLORECTAL CANCERS	GIST AND GASTRIC CANCER		
	☐ KIT et PDGFRA (OPL code KITPD)		
☐ KRAS-NRAS-BRAF-ERBB2-POLE (OPL code NGCOL)	☐ HER2, amplification by FISH (OPL code FSEIN)		
☐ KRAS-NRAS-BRAF (OPL code NGKNB)	☐ MSI (OPL code MSI)		
☐ KRAS-NRAS (OPL code NGRAS)	MMR status (IHC) if performed:		
☐ BRAF V600E (OPL code BRAVE)	☐ MET, amplification by FISH (OPL code FITOH)		
☐ MSI (OPL code MSI)	UROTHELIAL CANCERS		
MMR status (IHC) if performed:	☐ FGFR2/3 mutation (OPL code NGFLE)		
☐ Methylation status MLH1 (OPL code MEMLH)	☐ FGFR1, rearrangement by FISH (OPL code FITOH)		
	☐ FGFR2, rearrangement by FISH (OPL code FITOH)		
BRONCHOPULMONARY CANCERS	CHOLANGIOCARCINOMAS		
☐ EGFR, KRAS, BRAF, HER2, MET, STK11, KEAP1 (OPL code	☐ IDH1, mutations (OPL code NGIDH)		
NGPOU)	☐ FGFR1, rearrangement by FISH (OPL code FITOH)		
☐ ALK, ROS1, RET, NTRK1 to 3, MET, BRAF, FGFR1 to 3 Fusion/exon skipping detection by NGS (OPL code RNAFU)	☐ FGFR2, rearrangement by FISH (OPL code FITOH)		
☐ EGFR (exons 18 to 21) (OPL code EGFRL)	MSI (OPL code MSI)		
☐ Therapeutic target research	MMR status (IHC) if performed:		
☐ EGFR-TKI's restistance,	MELANOMAS □ BRAF+ NRAS+ C-KIT (OPL code NGMEL)		
Specify the treatment:	□ BRAF V600E (OPL code BRAVE)		
☐ EGFR-KRAS-BRAF(OPL code NGEKB)	DIGHT VOCCE (CI E COCC DIGHTE)		
ALK, translocation by FISH (OPL code ALKFI)	NEUROLOGY		
☐ ROS1, translocation by FISH (OPL code FIROS)	☐ 1p19q, deletion by FISH (OPL code FITOH)		
	☐ IDH1 and IDH2 (OPL code NGIDH)		
☐ MET, amplification by FISH (OPL code FITOH)	☐ IDH I and IDH2 (OPL code NGIDH)		
☐ MET, amplification by FISH (OPL code FITOH) GYNECOLOGICAL TUMORS	BREAST CANCERS		
·			
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD)	BREAST CANCERS		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20%	BREAST CANCERS □ Somatic BRCA1 and BRCA2 (OPL code BRCAS)		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN)		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors □ POLE, TP53 (OPL code NGPOL)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH)		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors POLE, TP53 (OPL code NGPOL) MSI (OPL code MSI)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN)		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors □ POLE, TP53 (OPL code NGPOL)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH)		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors POLE, TP53 (OPL code NGPOL) MSI (OPL code MSI) MMR status (IHC) if performed:	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH)		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors POLE, TP53 (OPL code NGPOL) MSI (OPL code MSI) MMR status (IHC) if performed: Please send us healthy tissue in addition to tumor tissue for joint study	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH) PIK3CA (OPL code NGPIK)		
GYNECOLOGICAL TUMORS Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors □ POLE, TP53 (OPL code NGPOL) □ MSI (OPL code MSI)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH) PIK3CA (OPL code NGPIK) PROSTATE CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS)		
Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors □ POLE, TP53 (OPL code NGPOL) □ MSI (OPL code MSI)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH) PIK3CA (OPL code NGPIK) PROSTATE CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) TESTS		
Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors □ POLE, TP53 (OPL code NGPOL) □ MSI (OPL code MSI)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH) PIK3CA (OPL code NGPIK) PROSTATE CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) TESTS		
Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors □ POLE, TP53 (OPL code NGPOL) □ MSI (OPL code MSI)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH) PIK3CA (OPL code NGPIK) PROSTATE CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) TESTS		
Ovarian / Peritoneal / Fallopian tube Tumors □ BRCA1/2 tumoral et Statut HRD (N454) (code OPL HRD) For HRD statut tumor cellularity must be >20% Endometrial tupors □ POLE, TP53 (OPL code NGPOL) □ MSI (OPL code MSI)	BREAST CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) HER2, amplification by FISH (OPL code FSEIN) ETV6, rearrangement by FISH (OPL code FITOH) PIK3CA (OPL code NGPIK) PROSTATE CANCERS Somatic BRCA1 and BRCA2 (OPL code BRCAS) TESTS		